Document is current
Any future updates will be listed below
-
Authors
Noonan, Megan L. http://orcid.org/0000-0002-1763-1867
Ni, Pu
Solis, Emmanuel
Marambio, Yamil G.
Agoro, Rafiou
Chu, Xiaona
Wang, Yue
Gao, Hongyu
Xuei, Xiaoling http://orcid.org/0000-0002-4143-2024
Clinkenbeard, Erica L.
Jiang, Guanglong http://orcid.org/0000-0002-9233-052X
Liu, Sheng
Stegen, Steve http://orcid.org/0000-0002-4471-6401
Carmeliet, Geert http://orcid.org/0000-0001-8324-4462
Thompson, William R. http://orcid.org/0000-0002-7022-585X
Liu, Yunlong
Wan, Jun
White, Kenneth E.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK112958, F31-DK122679)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL145528, T32-HL007910)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR059278, R01-AR074473)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Fonds Wetenschappelijk Onderzoek (FWO/12H5917N)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
- License Information
-
More Information
Article History
Received: 7 April 2022
Revised: 29 September 2022
Accepted: 3 November 2022
First Online: 18 January 2023
Competing interests
: KEW receives royalties for licensing FGF23 to Kyowa Hakko Kirin Co., Ltd; had previous funding from Akebia, and current funding from Calico Labs. KEW also owns equity interest in FGF Therapeutics. The other authors have nothing to declare.
